Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

UBS Initiates Coverage On Avadel Pharmaceuticals with Buy Rating, Announces Price Target of $21

Author: Benzinga Newsdesk | February 06, 2024 08:45am

UBS analyst Ashwani Verma initiates coverage on Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy rating and announces Price Target of $21.

Posted In: AVDL